Economic evaluation of pravastatin for primary prevention of coronary artery disease based on risk prediction from JALS-ECC in Japan

Value in Health Regional Issues

Volumn 2, Issue 1, 2013, Pages 5-12

  Onishi, Yoshie ^a   Hinotsu, Shiro ^a   Nakao, Yoko M ^b   Urushihara, Hisashi ^a   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Coronary artery disease; Cost effectiveness; Pravastatin; Primary prevention

Indexed keywords

PLACEBO; PRAVASTATIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DRUG COST; DRUG EFFICACY; FEMALE; HEART INFARCTION; HIDDEN MARKOV MODEL; HUMAN; HYPERTENSION; JAPAN; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS; SMOKING;

EID: 84877157581     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2013.02.003     Document Type: Article

References (35)

1. Ministry of Health, Labor and Welfare. National medical expenditure in 2009. Available from: . [Accessed November 20, 2011]. http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/09/kekka1.html.
2. Patients Survey in 2008. Japan: Ministry of Health, Labor and Welfare. [in Japanese].
3. Health Service Bureau, General Affairs Division, Ministry of Health, Labor and Welfare. National health and nutrition survey in 2008 [in Japanese].
4. The Global Drug Market of Hypertension and Hyperlipidemia. Osaka, Japan: Total Planning Center, 2008.
5. Teramoto T., Sasaki J., Ueshima H., et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007, 14:45-50.
6. World Health Organization. Disease and injury country estimates in 2004. Available from: . [Accessed November 20, 2011]. http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/.
7. Iso H., Sato S., Kitamura A., et al. Metabolic syndrome and the risk of ischemic heart disease and stroke among Japanese men and women. Stroke 2007, 38:1744-1751.
8. Lewington S., Whitlock G., et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007, 370:1829-1839. Prospective studies collaborations.
9. Koba S., Sasaki J. Treatment of hyperlipidemia from Japanese evidence. J Atheroscler Thromb 2006, 13:267-280.
10. Nakamura H., Arakawa K., Itakura H., et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomized controlled trial. Lancet 2006, 368:1155-1163.
11. Gotto A.M., Whitney E., Stein E.A., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000, 101:477-484.
12. Watts G.F. Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities. Curr Control Trials Cardiovasc Med 2001, 2:118-122.
13. D'Agostino R.B., Grundy S., Sullivan L.M., et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. Wilson P; CHD Risk Prediction Group. JAMA 2001, 286:180-187.
14. Guidelines for the Primary Prevention of Ischemic Heart Disease Revised Version. Japan, The Japanese Circulation Society, 2006.
15. Hashimoto A., Goto T., Uchibori M., et al. Risk and benefit of cholesterol lowering drugs to prevent coronary heart disease in Japan. J Jpn Atheroscler Soc 1998, 26:157-164.
16. Katayama T., Hisashige A. Economic evaluation of cholesterol lowering therapy for hypercholesterolemia, cost-effectiveness of HMG-CoA reductase inhibitors. Jpn Pharm Ther 1999, 27:747-758.
17. Kobayashi S., Shimbo T., Tatsui K., et al. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan. Int J Cardiol 2005, 104:213-223.
18. Ikeda S., Kobayashi M. Pharmacoeconomics of statin among hyperlipidemia patients. J Japan Healthcare Manag 2008, 8:521-525.
19. Brugts J., Tetgin T., Hoeks S., et al. The benefit of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. BMJ 2009, 338:b2376.
20. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421.
21. Tanabe N., Iso H., Okada K., et al. Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events - The JALS-ECC. Circ J 2010, 74:1346-1356.
22. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. World Health Organization, Hypertens. 1999;17:151-83.
23. Medical Fee Index, 2010 Edition. Japan: Igakutsushinsha, 2010.
24. National Health Insurance Drug Dictionary, 2010 Edition. JIHO, Japan: Yakugyo kenkyukai, 2010.
25. All Japan Hospital Association. Clinical outcome evaluation. Available from: . [Accessed February 5, 2011]. http://www.ajha.or.jp/hms/outcome/.
26. Tanihata S., Nishigaki K., Kawasaki M., et al. Outcomes of patients with stable low-risk coronary artery disease receiving medical- and PCI-preceding therapies in Japan: J-SAP study. Circ J 2006, 70:365-369.
27. Kang E., Ko S. A catalogue of EQ-5D utility weights for chronic diseases among noninstitutionalized community residents in Korea. Value Health 2009, 12:S114-S117.
28. Nonogi H. Current situation and prevention of ischemic sudden death in Japan. Diagnosis Treatment 2008, 96:2180-2184.
29. Vital Statistics of Japan. Japan: Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare, 2009.
30. Okusa Y., Sugawara Y. Research for willingness to pay for one QALY gain. Iryo to Shakai 2006, 16:157-165.
31. Briggs A., Claxton K., Sculpehr M. Decision Modeling for Health Economic Evaluation 2006, UK: Oxford University Press.
32. Bates T.R., Connaughton V.M., Watts G.F. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin Pharmacother 2009, 10:2973-2985.
33. Pravastatin sodium, JAPIC [package insert]. Available from: . [Accessed January 8, 2012]. http://www.genome.jp/kusuri/japic_med/show/00047960.
34. Tsevat J., Goldman L., Soukup J.R., et al. Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decis Making 1993, 13:161-165.
35. Greving J.P., Visseren F.L.J., de Wit G.A., et al. Stating treatment for primary prevention of vascular disease whom to treat? Cost-effectiveness analysis. BMJ 2011, 342. d1672.